Literature DB >> 27414259

The induction of autoimmune hepatitis in the human leucocyte antigen-DR4 non-obese diabetic mice autoimmune hepatitis mouse model.

M Yuksel1,2,3, X Xiao1,4, N Tai1, Manakkat Vijay1,3, E Gülden1, K Beland5, P Lapierre6, F Alvarez5, Z Hu4, I Colle2, Y Ma3, L Wen7.   

Abstract

Autoimmune hepatitis (AIH) is a chronic liver disease characterized by progressive inflammation, female preponderance and seropositivity for autoantibodies such as anti-smooth muscle actin and/or anti-nuclear, anti-liver kidney microsomal type 1 (anti-LKM1) and anti-liver cytosol type 1 (anti-LC1) in more than 80% of cases. AIH is linked strongly to several major histocompatibility complex (MHC) alleles, including human leucocyte antigen (HLA)-DR3, -DR7 and -DR13. HLA-DR4 has the second strongest association with adult AIH, after HLA-DR3. We investigated the role of HLA-DR4 in the development of AIH by immunization of HLA-DR4 (DR4) transgenic non-obese diabetic (NOD) mice with DNA coding for human CYP2D6/FTCD fusion autoantigen. Immunization of DR4 mice leads to sustained mild liver injury, as assessed biochemically by elevated alanine aminotransferase, histologically by interface hepatitis, plasma cell infiltration and mild fibrosis and immunologically by the development of anti-LKM1/anti-LC1 antibodies. In addition, livers from DR4 mice had fewer regulatory T cells (Tregs ), which had decreased programmed death (PD)-1 expression. Splenic Tregs from these mice also showed impaired inhibitory capacity. Furthermore, DR4 expression enhanced the activation status of CD8+ T cells, macrophages and dendritic cells in naive DR4 mice compared to naive wild-type (WT) NOD mice. Our results demonstrate that HLA-DR4 is a susceptibility factor for the development of AIH. Impaired suppressive function of Tregs and reduced PD-1 expression may result in spontaneous activation of key immune cell subsets, such as antigen-presenting cells and CD8+ T effectors, facilitating the induction of AIH and persistent liver damage.
© 2016 British Society for Immunology.

Entities:  

Keywords:  Tregs; autoantigen; transgenic-HLA-mouse model

Mesh:

Substances:

Year:  2016        PMID: 27414259      PMCID: PMC5054566          DOI: 10.1111/cei.12843

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  51 in total

1.  Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo.

Authors:  Janine Gotot; Catherine Gottschalk; Sonny Leopold; Percy A Knolle; Hideo Yagita; Christian Kurts; Isis Ludwig-Portugall
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-11       Impact factor: 11.205

2.  Genome-wide association study identifies variants associated with autoimmune hepatitis type 1.

Authors:  Ynto S de Boer; Nicole M F van Gerven; Antonie Zwiers; Bart J Verwer; Bart van Hoek; Karel J van Erpecum; Ulrich Beuers; Henk R van Buuren; Joost P H Drenth; Jannie W den Ouden; Robert C Verdonk; Ger H Koek; Johannes T Brouwer; Maureen M J Guichelaar; Jan M Vrolijk; Georg Kraal; Chris J J Mulder; Carin M J van Nieuwkerk; Janett Fischer; Thomas Berg; Felix Stickel; Christoph Sarrazin; Christoph Schramm; Ansgar W Lohse; Christina Weiler-Normann; Markus M Lerch; Matthias Nauck; Henry Völzke; Georg Homuth; Elisabeth Bloemena; Hein W Verspaget; Vinod Kumar; Alexandra Zhernakova; Cisca Wijmenga; Lude Franke; Gerd Bouma
Journal:  Gastroenterology       Date:  2014-04-23       Impact factor: 22.682

3.  Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission.

Authors:  Nicole M F van Gerven; Bart J Verwer; Birgit I Witte; Bart van Hoek; Minneke J Coenraad; Karel J van Erpecum; Ulrich Beuers; Henk R van Buuren; Rob A de Man; Joost P H Drenth; Jannie W den Ouden; Robert C Verdonk; Ger H Koek; Johannes T Brouwer; Maureen M J Guichelaar; Chris J J Mulder; Karin M J van Nieuwkerk; Gerd Bouma
Journal:  J Hepatol       Date:  2012-09-16       Impact factor: 25.083

Review 4.  Clinical significance of autoantibodies in autoimmune hepatitis.

Authors:  Rodrigo Liberal; Giorgina Mieli-Vergani; Diego Vergani
Journal:  J Autoimmun       Date:  2013-09-07       Impact factor: 7.094

Review 5.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

6.  Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease.

Authors:  Maria Serena Longhi; Yun Ma; Dimitrios P Bogdanos; Paul Cheeseman; Giorgina Mieli-Vergani; Diego Vergani
Journal:  J Hepatol       Date:  2004-07       Impact factor: 25.083

7.  Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization.

Authors:  K Wakabayashi; K Yoshida; P S C Leung; Y Moritoki; G-X Yang; K Tsuneyama; Z-X Lian; T Hibi; A A Ansari; L S Wicker; W M Ridgway; R L Coppel; I R Mackay; M E Gershwin
Journal:  Clin Exp Immunol       Date:  2008-12-15       Impact factor: 4.330

8.  Autoreactive human T-cell receptor initiates insulitis and impaired glucose tolerance in HLA DR4 transgenic mice.

Authors:  John A Gebe; Kellee A Unrath; Betty B Yue; Tom Miyake; Ben A Falk; Gerald T Nepom
Journal:  J Autoimmun       Date:  2007-10-18       Impact factor: 7.094

Review 9.  Immunoregulatory pathways controlling progression of autoimmunity in NOD mice.

Authors:  Sylvaine You; Marie-Alexandra Alyanakian; Berta Segovia; Diane Damotte; Jeffrey Bluestone; Jean-François Bach; Lucienne Chatenoud
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

10.  Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis.

Authors:  D G Doherty; P T Donaldson; J A Underhill; J M Farrant; A Duthie; G Mieli-Vergani; I G McFarlane; P J Johnson; A L Eddleston; A P Mowat
Journal:  Hepatology       Date:  1994-03       Impact factor: 17.425

View more
  8 in total

1.  Corrigendum.

Authors: 
Journal:  Clin Exp Immunol       Date:  2018-04       Impact factor: 4.330

2.  A novel insight into the pathophysiology of autoimmune hepatitis: An immune activator mutation in the FLT3 receptor.

Authors:  Muhammed Yuksel; Ayse Armutlu; Farinaz Nazmi; Serdar Ceylaner; Cigdem Arikan
Journal:  Hepatol Forum       Date:  2021-09-07

Review 3.  Regulatory T cells in autoimmune hepatitis: an updated overview.

Authors:  Maria Serena Longhi; Giorgina Mieli-Vergani; Diego Vergani
Journal:  J Autoimmun       Date:  2021-02-27       Impact factor: 7.094

Review 4.  Animal Models for Autoimmune Hepatitis: Are Current Models Good Enough?

Authors:  Urs Christen; Edith Hintermann
Journal:  Front Immunol       Date:  2022-07-12       Impact factor: 8.786

5.  Study on the interaction mechanism between C-reactive protein and platelets in the development of acute myocardial infarction.

Authors:  Yubao Liu; Shuhui Lai; Lijie Liang; Donghai Zhang
Journal:  Ann Transl Med       Date:  2021-06

6.  Plasma proteomic analysis of autoimmune hepatitis in an improved AIH mouse model.

Authors:  Han Wang; Wei Yan; Zuohua Feng; Yuan Gao; Liu Zhang; Xinxia Feng; Dean Tian
Journal:  J Transl Med       Date:  2020-01-06       Impact factor: 5.531

Review 7.  Regulatory T Cells in Autoimmune Hepatitis: Unveiling Their Roles in Mouse Models and Patients.

Authors:  Han Wang; Xinxia Feng; Wei Yan; Dean Tian
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

Review 8.  Autoimmmune hepatitis.

Authors:  Benedetta Terziroli Beretta-Piccoli; Giorgina Mieli-Vergani; Diego Vergani
Journal:  Cell Mol Immunol       Date:  2021-09-27       Impact factor: 11.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.